Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes therapeutic advances reported in English-language literature from December 1987 to December 1988 and states no new clinical results.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

In this case report, a 28-year-old woman's tinea capitis, diagnosed using a Wood's lamp, was successfully treated with oral itraconazole and ketoconazole shampoo over eight weeks.

This review discusses current anti-inflammatory treatment options for calcium pyrophosphate crystal deposition disease (CPPD) and highlights the lack of crystal-targeted therapies, emphasizing the need for more research to guide treatment.

This study found that topical corticosteroid foams are effective and generally preferred by patients for a variety of corticosteroid-responsive skin conditions, demonstrating significant clinical benefits such as improved psoriasis symptoms and hair regrowth in alopecia areata compared to traditional forms.

New acne treatments include combination creams, advanced retinoids, and light therapies, focusing on safety and patient adherence.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

This study found that 1-day itraconazole therapy was more effective for acute vulvovaginal candidosis than for recurrent cases, where relapses occurred despite no yeast resistance.

Collagen CLR and placenta extract may help treat diffuse hair loss.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

This clinical study found that using a cream or lotion as an additional treatment alongside standard care for atopic dermatitis significantly reduced symptoms and improved skin moisturization and barrier function within 28 days compared to standard care alone in participants with mild-to-moderate eczema.

This study found that monochromatic excimer light achieved complete remission in over 50% of plaque psoriasis cases and various levels of improvement in other skin conditions, including vitiligo and mycosis fungoides.

This case study of a patient with dissecting cellulitis of the scalp found that multiple medications, including isotretinoin, achieved only modest improvement, and symptoms returned after treatments were stopped.

This article discusses tretinoin, noting its approved use for acne and photoaging and its broader application in treating various dermatological conditions, but reports no new clinical findings.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

This study found that 2-hydroxy-1,4-naphthoquinone was the most effective inhibitor of steroid 5α-reductase, showing stronger inhibition than avicequinone C in HaCaT cell assays.

This study found that Aminexil clinical 5 significantly reduced hair loss in men and women with mild alopecia and was well tolerated with high subject satisfaction.

The chemical peel improved the appearance of hand spots safely and effectively.

This review discusses the potential role of a PADI3 gene variant in central centrifugal cicatricial alopecia among African-American women but reports no new clinical results.

This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.

In this case report, a patient with diffuse alopecia areata experienced complete hair regrowth after treatment with oral abrocitinib, with no adverse effects observed.

This study reported that specific inhibition of the classical complement pathway with BIVV009 prevented C3 deposition along the dermal-epidermal junction in bullous pemphigoid, reflecting its potential efficacy.

This study found that oral isotretinoin was effective and safe for treating acne vulgaris in a dermatology clinic in Aden, with 80.2% of patients achieving complete clearance and significant differences in acne severity based on age groups.

This study found that nearly 40% of patients with severe alopecia areata who showed eyebrow or eyelash regrowth on baricitinib 4 mg achieved significant scalp hair regrowth by the second year of treatment.

In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy, suggesting a rare association between the drug and these immune-mediated skin conditions, highlighting the potential benefit of early intervention with baricitinib.

This case report describes a 40-year-old man whose vitiligo and psoriasis responded favorably to ixekizumab after experiencing vitiligo onset and psoriasis relapse during adalimumab treatment.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

In this open-label trial, 9-cis-retinoic acid showed moderate activity against Kaposi sarcoma in AIDS patients, but its use is limited by substantial side effects at higher doses.

This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.